Genetic diversity of carbapenem-hydrolysing β-lactamases in Acinetobacter baumannii from Romanian hospitals  by Bonnin, R.A. et al.
Figure S1. Pulse ﬁeld gel electrophoresis patterns of
blaKPC-2 isolates.
Table S1. Primers used in PCR mapping of blaKPC-2
genetic environments.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the article.
References
1. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella
pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-
resistant infection. J Antimicrob Chemother 2010; 65: 1119–1125.
2. Kitchel B, Rasheed JK, Patel JB et al. Molecular epidemiology of KPC-
producing Klebsiella pneumoniae isolates in the United States: clonal
expansion of multilocus sequence type 258. Antimicrob Agents Chemo-
ther 2009; 53: 3365–3370.
3. Leavitt A, Carmeli Y, Chmelnitsky I, Goren MG, Ofek I, Navon-Vene-
zia S. Molecular epidemiology, sequence types, and plasmid analyses
of KPC-producing Klebsiella pneumoniae strains in Israel. Antimicrob
Agents Chemother 2010; 54: 3002–3006.
4. Lopez JA, Correa A, Navon-Venezia S et al. Intercontinental spread
from Israel to Colombia of a KPC-3-producing Klebsiella pneumoniae
strain. Clin Microbiol Infect 2011; 17: 52–56.
5. Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P.
Genetic structures at the origin of acquisition of the b-lactamase
blaKPC gene. Antimicrob Agents Chemother 2008; 52: 1257–1263.
6. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumo-
niae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9:
228–236.
7. Shen P, Wei Z, Jiang Y et al. Novel genetic environment of the carba-
penem-hydrolyzing b-lactamase KPC-2 among Enterobacteriaceae in
China. Antimicrob Agents Chemother 2009; 53: 4333–4338.
8. Qi Y, Wei Z, Ji S, Du X, Shen P, Yu Y. ST11, the dominant clone of
KPC-producing Klebsiella pneumoniae in China. J Antimicrob Chemother
2011; 66: 307–312.
9. Pasteran FG, Otaegui L, Guerriero L et al. Klebsiella pneumoniae carb-
apenemase-2, Buenos Aires, Argentina. Emerg Infect Dis 2008; 14:
1178–1180.
10. Pasteran F, Mendez T, Guerriero L, Rapoport M, Corso A. Sensitive
screening tests for suspected class A carbapenemase production in
species of Enterobacteriaceae. J Clin Microbiol 2009; 47: 1631–1639.
11. Pasteran F, Mendez T, Rapoport M, Guerriero L, Corso A. Control-
ling false-positive results obtained with the Hodge and Masuda assays
for detection of class a carbapenemase in species of Enterobacteria-
ceae by incorporating boronic acid. J Clin Microbiol 2010; 48: 1323–
1332.
12. Melano R, Corso A, Petroni A et al. Multiple antibiotic-resistance
mechanisms including a novel combination of extended-spectrum
b-lactamases in a Klebsiella pneumoniae clinical strain isolated in
Argentina. J Antimicrob Chemother 2003; 52: 36–42.
13. van Belkum A, Tassios PT, Dijkshoorn L et al. Guidelines for the vali-
dation and application of typing methods for use in bacterial epidemi-
ology. Clin Microbiol Infect 2007; 13 (suppl 3): 1–46.
14. Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. Multilocus
sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin
Microbiol 2005; 43: 4178–4182.
15. Tijet N, Andres P, Chung C et al. rmtD2, a new allele of a 16S rRNA
methylase gene, has been present in Enterobacteriaceae isolates from
Argentina for more than a decade. Antimicrob Agents Chemother 2011;
55: 904–909.
16. Rhodes G, Parkhill J, Bird C et al. Complete nucleotide sequence of
the conjugative tetracycline resistance plasmid pFBAOT6, a member
of a group of IncU plasmids with global ubiquity. Appl Environ Microbiol
2004; 70: 7497–7510.
17. Cuzon G, Naas T, Truong H et al. Worldwide diversity of Klebsiella
pneumoniae that produce b-lactamase blaKPC-2 gene. Emerg Infect Dis
2010; 16: 1349–1356.
18. Nakamura M, Sato S, Ohya T, Suzuki S, Ikeda S. Plasmid proﬁle analy-
sis in epidemiological studies of animal Salmonella typhimurium infec-
tion in Japan. J Clin Microbiol 1986; 23: 360–365.
19. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. Iden-
tiﬁcation of plasmids by PCR-based replicon typing. J Microbiol Meth-
ods 2005; 63: 219–228.
20. Clinical and Laboratory Standards Institute. Performance standards for
antimicrobial susceptibility testing; twentieth informational supplement.
CLSI M100-S20-U Vol. 30 No. 15. Wayne, PA: CLSI, 2010.
Genetic diversity of carbapenem-
hydrolysing b-lactamases in Acinetobacter
baumannii from Romanian hospitals
R. A. Bonnin1, L. Poirel1, M. Licker2 and P. Nordmann1
1) Service de Bacte´riologie-Virologie, INSERM U914 ‘Emerging Resistance
to Antibiotics’, Hoˆpital de Biceˆtre, Assistance Publique/Hoˆpitaux de Paris,
Faculte´ de Me´decine et Universite´ Paris-Sud, K. Biceˆtre, France and
2) Department of Microbiology, University of Medecine and Pharmacy
Victor Babes, Timisoara, Romania
Abstract
Thirteen carbapenem-resistant Acinetobacter baumannii isolates,
collected in Romania during 2009–2010, were investigated to
identify the mechanism(s) responsible for carbapenem resistance.
Genotyping was performed by pulsed-ﬁeld gel electrophoresis,
multiplex PCR sequence typing and multilocus sequence typing.
Eleven non-clonally related isolates harboured the blaOXA-23
gene on their chromosome within a Tn2008 transposon struc-
ture. The two remaining isolates harboured a blaOXA-58 gene
that was either plasmid or chromosome borne. Two isolates
co-expressed OXA-23 together with the extended-spectrum
b-lactamase PER-1. This study constitutes the ﬁrst report of
OXA-58 and OXA-23-producing A. baumannii isolates in
Romania.
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Carbapenem resistance has been reported increasingly in
Acinetobacter baumannii isolates [1], and that resistance trait
is often related to the production of carbapenem-hydroly-
sing class D b-lactamases (CHDL) that are disseminated
worldwide [2]. Five groups of CHDLs have been identiﬁed
to date in A. baumannii, namely OXA-23, OXA-24/-40,
OXA-51, OXA-58 and OXA-143 [3], although OXA-51 and
its derivatives correspond to naturally occurring b-lactamas-
es in that species [3,4]. Outbreaks of CHDL-producing
A. baumannii isolates have been reported for OXA-24/-40 in
Spain and the USA [5,6] and for OXA-58 in France and
Greece [7,8]. OXA-23 is the most commonly identiﬁed
CHDL worldwide [9], and the corresponding gene is
located on either plasmids or on the chromosome, and
associated with ISAba1 or ISAba4 insertion sequences at the
origin of its acquisition [9]. Although resistance to carba-
penems is mostly related to production of CHDLs and me-
tallo-b-lactamases (even at a lower level), the resistance to
broad-spectrum cephalosporins in A. baumannii mostly
results from overexpression of the natural AmpC-type
enzyme [10] or from acquisition of the extended-spectrum
b-lactamases (ESBLs) genes, namely blaPER-like, blaVEB-1 and
blaGES-like genes [11–17].
The aim of the study was to analyse a collection of carba-
penem-resistant A. baumannii isolates recovered from three
hospitals located in Arad, Resita and Timisoara, western
Romania, between February 2009 and November 2010 (as
part of a Romanian national surveillance project). Thirteen
carbapenem-resistant A. baumannii were recovered from
bronchial aspirates, wound secretions, urines or central vas-
cular catheters of patients hospitalized in intensive care units
in those three hospitals (Table 1).
The isolates were identiﬁed by 16S rRNA gene sequencing
[18]. Susceptibility testing was performed by disc diffusion
assay (Sanoﬁ-Diagnostic Pasteur, Marnes-la-Coquette,
France) and interpreted according to CLSI guidelines [19].
The MICs of b-lactams including imipenem, meropenem and
doripenem and colistin were determined by Etest (AB bio-
Me´rieux, Solna, Sweden), as described [11]. MICs of carba-
penems ranged from 4 to up to 32 mg/L. In addition, these
isolates were resistant to almost all antibiotics, including ﬂur-
oquinolones, aminoglycosides and b-lactams (Table 2), but all
isolates remained susceptible to rifampin and colistin (MIC of
0.5 mg/L). The production of MBLs was evaluated using
Etest, combining imipenem and EDTA as recommended by
the manufacturer (AB bioMe´rieux) and the combined disc
test, which is also based on inhibition of MBL activity by
EDTA. Two imipenem discs (10 lg), with one containing
10 lL of 0.1 M anhydrous EDTA, were placed 25 mm apart
on a Mueller–Hinton plate as recently described [20]. All iso-
lates remained negative for MBL production. PCR experi-
ments followed by sequence analysis led to the identiﬁcation
of the blaOXA-23 gene in 11 isolates and the blaOXA-58 gene in
two isolates, in addition to a natural blaOXA-51-like gene iden-
tiﬁed in all isolates (Table 1).
TABLE 1. Clinical features, b-lactamase detection and genotyping of Acinetobacter baumannii clinical isolates
Isolates
Date of
isolation Unit, town Sample OXA-23 OXA-58 PER-1
ISAba1-
ampC TEM-1
OXA-51-
like EC//ST Pulsotype
Acb2 11/06/09 SCJUTa, Timisoara Bronchial aspirate + ) ) + + OXA-69 I/1 A
Acb5 16/02/09 SCJUAa, Arad Wound secretion + ) ) + ) OXA-69 I/1 A
Acb9 12/01/10 SCPTa, Timisoara Bronchial aspirate + ) ) + + OXA-66 II/2 B
Acb13 12/03/10 SCJUTa, Timisoara Urine culture + ) + + + OXA-66 II/2 D
Acb14 12/03/10 SCPTa, Timisoara Central vascular cathether + ) ) + ) OXA-66 II/2 B
Acb15 16/03/10 SCJUTa, Timisoara Bronchial aspirate + ) + + + OXA-66 II/2 D
Acb16 23/03/10 SCJUTa, Timisoara Catheter tip ) + ) + ) OXA-64 nt/110 E
Acb19 05/03/10 SCJUTa, Timisoara Blood culture ) + ) + ) OXA-69 I/1 C
Acb20 10/11/10 SCJUAa, Arad Pus + ) ) + ) OXA-69 I/1 C
Acb21 05/05/10 SCPTa, Timisoara Bronchial aspirate + ) ) + ) OXA-66 II/2 B
Acb22 27/10/10 SCJURa, Resita Bronchial aspirate + ) ) + + OXA-66 II/2 B
Acb24 05/11/10 SCJUAa, Arad Bronchial aspirate + ) ) + + OXA-66 II/2 B
Acb25 17/11/10 IBCVTa, Timisoara Bronchial aspirate + ) ) + ) OXA-69 I/1 C
nt, not typeable.
aIBCVT, Timisoara Institute of Cardiovascular Diseases (Timisoara); SCJUT, Timisoara Emergency Clinical County Hospital (Timisoara); SCJUA, Arad Emergency Clinical
County Hospital (Arad); SCJUR, Resita Emergency Clinical County Hospital (Resita); SCPT, Timisoara Clinical Paediatric Hospital (Timisoara).
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Synergy tests with discs containing ceftazidime and ticarcil-
lin-clavulanic acid, using cloxacillin containing Mueller–Hinton
agar plates as described [12], gave positive results for two
isolates. PCR followed by sequencing identiﬁed the
extended-spectrum b-lactamase (ESBL) blaPER-1 gene in those
isolates (Table 1). The blaVEB-1 gene and the blaGES-1 gene
were also screened but were not identiﬁed. The insertion
sequence ISAba1 was detected upstream of the blaOXA-23
gene in all positive isolates but no ISAba1 was detected
downstream of the blaOXA-23 gene, ruling out the hypothesis
that this gene could be part of composite transposon
Tn2006. Sequence analysis of the region separating ISAba1
from the blaOXA-23 gene revealed a 7-bp deletion, corre-
sponding to the sequence previously identiﬁed in Tn2008
carrying blaOXA-23 in A. baumannii isolates from the USA and
China [21]. In addition, ISAba1 was identiﬁed upstream of
the naturally-occurring cephalosporinase gene blaADC, indicat-
ing that this gene was overexpressed in all isolates, leading
to resistance to extended-spectrum cephalosporins. In con-
trast, no colinearity was found between ISAba1 and the
blaOXA-51 gene in any isolate. For isolates Acb16 and 19, the
blaOXA-58 gene was associated with one copy of ISAba3 iden-
tiﬁed at its 5¢-extremity as described previously [22].
Genotypic comparison was performed by multilocus
sequence typing (MLST), sequence-type multiplex PCR and
pulsed-ﬁeld gel electrophoresis (PFGE) according to the
manufacturer’s recommendations (Bio-Rad, Marnes-la-
Coquette, France). PFGE analysis performed with a CHEF
DRII apparatus as described [23] showed that the 13 isolates
corresponded to ﬁve distinct clones named A to E (Fig. 1).
The blaOXA-23-positive isolates belonged to clones A to D
whereas the two blaOXA-58-positive isolates belonged to
clones C and E (Table 1). Further analysis with sequence-
type multiplex PCR as described by Turton et al. [24]
showed that clones A and C corresponded to European
clone I, clones B and D to the widespread European clone II,
and clone E did not correspond to any deﬁned European
clone (Table 1). For clone E, only two positive ampliﬁcations
were observed with group 1 csuE and blaOXA-51-like primers,
respectively. MLST analysis performed for each clone as
described by Diancourt et al.[25] showed that clones A and
C belonged to the ST type ST1, clones B and D belonged
to ST2 and clone E to a new ST type named ST110 (http://
www.pasteur.fr/cgi-bin/genopole/PF8/mlstdbnet.pl?ﬁle=acin_
isolates.xml).
TABLE 2. MICs of b-lactams for A. baumannii isolates, transformant and A. baumannii BM4547 reference strain
b-lactams
MIC (lg/mL)
A. baumannii
Acb2
A. baumannii
Acb9
A. baumannii
Acb13
A. baumannii
Acb16
A. baumannii
Acb19
A. baumannii
Acb20
A. baumannii
BM4547
pAcb19
A. baumannii
BM4547
Ticarcillin >256 >256 >256 >256 >256 >256 >256 8
Ticarcillin + CLA >256 >256 >256 >256 >256 >256 >256 8
Piperacillin >256 >256 >256 >256 >256 >256 256 4
Piperacillin + TZP >256 >256 >256 >256 >256 >256 128 4
Cefalothin >64 >64 >64 >64 >64 >64 >64 >64
Cefuroxime >64 >64 >64 >64 >64 >64 64 64
Cefoxitin >64 >64 >64 >64 >64 >64 >64 >64
Cefotaxime >64 >64 >64 >64 >64 >64 >32 >32
Ceftazidime >64 >64 >64 >64 >64 32 4 4
Cefepime >64 >64 >64 16 >64 >64 16 16
Cefpirome >64 >64 >64 32 >64 64 64 64
Meropenem >32 >32 32 16 4 >32 2 0.5
Doripenem 24 >32 24 6 4 >32 2 0.25
Imipenem >32 >32 32 24 4 >32 2 0.25
CLA, clavulanic acid (4 lg/mL); TZB, tazobactam (4 lg/mL).
A1 A2 B1 B2 C1 B3 B4 B5 C2 D1 D2 E1 C3 L
291 kb
339.5 kb
194 kb
242.5 kb
145.5 kb
97 kb
48.5 kb
FIG. 1. Pulsed-ﬁeld gel electrophoresis (PFGE) pattern of OXA-23
and OXA-58 producing Acinetobacter baumannii isolates. Lanes A–E,
ﬁve pulsotypes obtained by PFGE after digestion with ApaI. Lanes
A1–A2, B1–B5, C1–C3 and D1–D2 correspond to subtypes of puls-
otypes A, B, C and D, respectively.
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In order to determine the genetic location of the
blaOXA-23 and blaOXA-58 genes, plasmid DNA of the different
A. baumannii clones was extracted by using the Kieser
method [11] and Southern hybridization was performed by
using internal PCR amplicons as probes for blaOXA-23 and
blaOXA-58 genes. Only one isolate, Acb 19, harbouring the
blaOXA-58 gene gave a positive result, suggesting that the
CHDL encoding genes were chromosomally encoded in
other isolates (data not shown).
Transfer of the ticarcillin resistance marker into A. bau-
mannii BM4547 was attempted by liquid mating-out assays at
37C and by electroporation of a plasmid DNA suspension
extracted from an A. baumannii clinical isolate into A. bau-
mannii BM4547 overproducing the efﬂux system AdeABC.
Selection was performed on agar plates supplemented with
ticarcillin (100 lg/mL). Those experiments failed except with
A. baumannii Acb19, for which a transformant was obtained
with a c. 20-kb blaOXA-58-positive plasmid. Plasmid extraction
showed that all isolates harboured a large plasmid of c.
150 kb, and isolates Acb2, Acb20 and Acb25 harboured an
additional plasmid of c. 10 kb. No transformant or transcon-
jugant was obtained that harboured the blaPER-1 gene, sug-
gesting a chromosomal location of that gene.
Here, we identiﬁed carbapenemase-producing A. baumannii
isolates from Romania. The carbapenemases identiﬁed were
either OXA-23 or OXA-58, previously identiﬁed worldwide
in A. baumannii. Interestingly, we showed here that some
carbapenemase producers additionally co-produced an ESBL.
Also, it was noteworthy that one given clone strain might
express OXA-23 or OXA-58, showing that different carba-
penemase genes may be acquired by a same clone in a given
location. These results ﬁt with published antibiotic resistance
data for Central Europe showing OXA-58 and OXA-40 in
the Czech Republic, OXA-23 and OXA-58 in Bulgaria and
OXA-72 in Croatia, whereas an NDM-1 producer A. bau-
mannii was detected in Serbia [25–29]. That study further
underlines that CHDL represent the most common mecha-
nisms of resistance to carbapenems in that species.
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Microbiological diagnosis of prosthetic joint
infections: a prospective evaluation of four
bacterial culture media in the routine
laboratory
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Abstract
The diagnosis of prosthetic joint infection (PJI) in the routine
microbiology laboratory is labour-intensive, but semi-automated
methods may be appropriate. We prospectively compared four
microbiological culture methods on samples taken at prosthetic
joint revision surgery. Automated BACTEC blood culture bot-
tles and cooked meat enrichment broth were the most sensitive
methods (87% and 83%, respectively, as compared with fastidi-
ous anaerobic broth (57%) and direct plates (39%)); all were
highly speciﬁc (97–100%). To our knowledge, this is the ﬁrst
prospective study aimed at comparing culture methods in rou-
tine use in UK clinical laboratories for the diagnosis of PJI.
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Microbiological diagnosis of prosthetic joint infection (PJI) is
complex and laborious [1–5]. Automated blood culture bot-
tles have been used for synovial ﬂuid [6,7] but not for tissue
suspensions.
This study was designed to compare the sensitivity and
speciﬁcity for PJI of the following four microbiological culture
media: direct plates; the enrichment medium of our local
standard operating procedure (Robertson’s cooked meat
broth (CM)); an alternative enrichment medium (fastidious
anaerobic broth (FA) [8]); and automated BACTEC blood
culture bottles.
The study was performed at the Oxford Radcliffe Hospital
(ORH) NHS Trust Microbiology laboratory, which serves
both the ORH Trust and the Nufﬁeld Orthopaedic Centre.
All joint revisions performed between December 2006 and
September 2007 were included prospectively.
Surgeons collected multiple intra-operative specimens
according to an established protocol. These were trans-
ported immediately to the laboratory for processing [9].
Gram stains were not performed. Previous experience had
shown these to be poorly sensitive for PJI [9].
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